Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Sanofi MS drug nears green light after pass-the-parcel marathon
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Good Early Results for HERV Suppressor in MS
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Laquinimod Phase IIa Study in Active Crohn's Disease
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Imaging Neurodegeneration and Repair in Multiple Sclerosis
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Genetics of multiple sclerosis: swimming in an ocean of data.

Pages